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Abstract   
     We functionally characterized the motor 
domains of five dilated cardiomyopathy 
(DCM)-FDXVLQJPXWDWLRQVLQKXPDQȕ-cardiac 
myosin. Analysis of the kinetics of the 
individual events in the ATPase cycle, reveal 
that each mutation alters different steps in the 
cycle, depending upon its location. For 
example, different mutations have enhanced or 
reduced rate constants of ATP binding, ATP 
hydrolysis or ADP release or show altered 
ATP, ADP or actin affinity. Thus, local effects 
dominate and no common pattern accounts for 
the similar clinical phenotype resulting from 
each mutation. Nor is there a distinct set of 
changes that distinguish DCM mutations from 
the hypertrophic cardiomyopathy (HCM) 
myosin mutations we have previously 
analyzed. However, when using the data for 
each step in the cycle to model the complete 
ATPase contraction cycle, some themes do 
emerge. The DCM mutations result in a lower 
duty ratio (the portion of the ATPase cycle 
when myosin is strongly bound to actin) for 4 
out of 5 mutations due to reduced occupancy 
of the force-holding, AM.ADP complex in the 
steady-state. Under load, the AM.ADP state is 
predicted to increase due to a reduced rate 
constant for ADP release, and this effect is 
blunted for all five DCM mutations. 
Additionally, the data predict a higher 
efficiency of ATP usage for the DCM mutants 
compared to WT and HCM mutants. This 
result predicts that sarcomeres expressing 
myosin with DCM mutations would have 
impaired force generation and force-holding 
capacity. We see the opposite effect when 
comparing with kinetic data for two HCM 
mutations, namely R403Q and R453C 
Introduction   
        Dilated cardiomyopathy (DCM) and 
hypertrophic cardiomyopathy (HCM) are 
significant causes of arrhythmias, heart failure 
and sudden cardiac death (1). While many 
cases are idiopathic, mutations in proteins of 
WKH FDUGLDF VDUFRPHUH LQFOXGLQJ ȕ-cardiac 
myosin, can cause both diseases. DCM is 
characterized by a dilated ventricular cavity 




with systolic dysfunction and is a very 
heterogeneous disease from an etiologic 
standpoint. HCM is characterized by preserved 
or enhanced systolic function and significant 
hypertrophy (2±4). 
      While most mutations that cause HCM are 
in sarcomeric proteins, the genetics of familial 
DCM are much more diverse, with mutations 
in titin being the most common (5, 6). That 
said, more than 30% of HCM-causing 
mutations and 3-4% of DCM-causing 
PXWDWLRQV DUH IRXQG LQ WKH ȕ-myosin heavy-
chain gene, MYH7 (6, 7). DCM-causing 
PXWDWLRQV LQ WKH ȕ-cardiac myosin gene are 
found in different domains of the motor and in 
the tail region, although penetrance of the tail 
region mutations is incomplete (8). We 
selected 5 DCM-causing PXWDWLRQV LQ WKH ȕ-
cardiac myosin motor domain for study (their 
locations in the motor domain are shown in 
Fig 1). These include S532P and F764L (9). 
Affected individuals presented with early-
onset ventricular dilatation without antecedent 
symptoms or signs of hypertrophy and often 
progressed to in heart failure. A223T was 
identified in a 35-year-old male DCM patient 
(10). R237W, a possible disease-causing 
mutation, was identified in a patient with 
familial DCM (11). The fifth DCM mutation 
we chose to study is I201T which can cause 
ventricular dilatation with or without systolic 
dysfunction (12) .   
 
        In our previous studies, we completed 
detailed characterization of the biochemical 
and chemo-PHFKDQLFDOSURSHUWLHVRIKXPDQȕ-
cardiac myosin motor domains carrying either 
R403Q or R453C HCM mutations (13±15). 
For R453C, while there was a decrease in 
ATPase activity and in vitro motility, there 
was a 50% increase in intrinsic force (13). 
Kinetic measurements of this mutant motor 
showed subtle perturbations. The exceptions 
were the rate constants for ATP binding 
(reduced by 35%) and the ATP hydrolysis 
step/recovery stroke (slowed 3-fold) (15). In 
contrast, the human R403Q mutant motor 
showed an overall loss of function (14). We 
SXEOLVKHG D PRGHOLQJ DQDO\VLV RI WKH :7 ȕ-
cardiac S1 and the HCM mutation, R453C 
(16) which demonstrated that such detailed 
kinetic information on the individual 
molecular events in the ATPase cycle can be 
used to model the complete mechanochemical 
cycle and predict some of the properties of the 
motor such as maximum shortening velocity, 
and the load-dependence of force holding 
states. In principle, the same approach should 
allow us to define how missense mutations 
alter the mechanochemical cycle and may 
provide insights into how mutations can cause 
different cardiac phenotypes.  
     While many cell and mouse models have 
been made for HCM cardiac myosin mutations 
(17±19), there are fewer studies on myosin 
mutations that cause DCM. Two mouse 
models have been described: S532P and 
F764L and some of the biochemical properties 
of myosin purified from the hearts of these 
mice have been described (20, 21). Contractile 
function was reduced and purified mutant 
myosin from mouse hearts showed decreased 
actin activated ATPase and in vitro motility. It 
is important to note that both of these models 
were made placing mutations into the mouse 
Į-cardiac myosin gene as opposed to the 
KXPDQ ȕ-cardiac myosin gene. This point 
stems from the observation that the R403Q 
mutation was shown to have very different 
HIIHFWV LQ WKH FRQWH[W RI Į-cardiac myosin 
FRPSDUHGWRȕ-cardiac myosin (14, 22). 
        Here we report detailed biochemical 
characterization and mechanochemical cycle 
modeOOLQJ RI UHFRPELQDQW KXPDQ ȕ-cardiac 
myosin motor-domains carrying five DCM 
mutations. The data are compared with our 
SUHYLRXVGDWDRQWKHKXPDQȕZLOG-type (WT) 
and the motor domain carrying either of two 
well-known HCM mutations (14, 15). Since 
each of these mutations produces clinically 
related hypocontractile DCM phenotypes, we 
might expect to see similar alterations in the 
properties of the mutant myosin motor 
domain, and we predict that these will be 
distinct from those seen for mutations that 
cause HCM. Our data indicate that each 
mutation has its own distinct effects on 
individual steps of the mechanochemical 
cycle, and the pattern of changes shows no 
commonality between DCM-linked mutations 
or distinct differences between DCM and 
HCM mutations. However, when the complete 
cycle is modelled, distinct behaviors do 
emerge. DCM mutations have lower 
occupancy of the force holding AÂMÂD state in 
the steady-state than WT or the HCM 
mutations for 4 out of 5 DCM mutations. This 




predicts a lower duty ratio for the DCM 
mutations and a stronger effect of load on the 
cycle. Our analysis also suggests that DCM 
mutations use less ATP than WT in generating 
high force or high velocities. In contrast, the 
two HCM mutations have a similar efficiency 
as WT for force generation and they are less 
efficient for high velocity contraction. 
Results 
Location of the 5 mutations in the structure of 
the motor domain  
     The five DCM mutations studied here were 
selected because they are located in quite 
distinct regions of the motor domain, are 
highly conserved across myosins and yet all 
cause DCM (Fig 1 A & B).  Three of the 
mutations are in the upper 50 kDa domain 
close to regions that may influence nucleotide 
binding. I201 (mutated to T) is at the end of a 
helix that links the P-loop (binds the Ȗ Pi of 
ATP) to the start of Loop 1, a surface loop 
known in many myosins as a variable loop that 
can influence the affinity of ADP for myosin 
and actin.myosin. For a review of structures 
see (23±25). A223 (mutated to T) is a buried 
residue near the ATP binding site, in a helix 
just after Loop 1 and the helix has potential 
interactions with major structural elements in 
the upper 50 kDa domain such as Helix O 
(which links the actin-binding cardiomyopathy 
loop to the nucleotide pocket) and the central 
ȕ-sheet (strand 7). R237 (mutated to W) is just 
before Switch 1, a highly conserved region 
responsible for binding to the Ȗ phosphate of 
ATP. Closing of Switch 1 onto ATP results in 
opening of the large cleft through the upper 50 
kDa domain. This cleft spans the actin binding 
site and opening the cleft destroys the ability 
of myosin to bind strongly to actin. The 
change from the charged arginine to 
hydrophobic tryptophan could cause disruption 
in the local structure and movement of Switch 
1. The identical mutation in human myosin 1C 
(R156W) is reported to be associated with 
bilateral sensorineural hearing loss (26). S532 
(mutated to P) is in a small helix in the lower 
50kDa domain just before the actin binding 
Loop 3. Finally, F764 (mutated to L) is in the 
converter region which moves with the lever 
arm as the motor goes through its power stroke 
and its reversal, the recovery stroke (which is 
coupled to the ATP hydrolysis step). Thus, 
each mutation has the potential to perturb local 
interactions which are important for the 
efficient operation of the motor. The long-term 
question we are interested in is how each of 
these mutations in distinct domains results in 
similar clinical phenotypes.   
 
Transient kinetic data 
     In our previous studies, we completed a 
detailed characterization of the events in the 
myosin and actin.myosin ATPase for human 
ȕ-S1 and the S1 carrying either R403Q or 
R453C mutations associated with HCM (14, 
15). We were able to measure the rate and 
equilibrium constants for most of the events 
shown in Fig 3 & 4 and used these together 
with steady-state ATPase data to model the 
behaviour of the WT and R453C mutation 
(16). Here we have taken the same approach to 
understand the molecular impact of the five 
DCM mutations. 
 
     The experimental methods and analysis 
tools used for the transient kinetic experiments 
have been extensively described in our 
previous publications (15, 27±29).  The type of 
data, the quality of the signals, the reliability 
of the fitting programs and assignments of 
fitted constants have previously been 
described (14, 15). In the interest of brevity, 
we present a summary of the data here with 
details of each measurement given in the 
supplementary information. The data are 
summarized in Table 1. Each assay was 
completed a minimum of three times with at 
least two different preparations purified from 
C2C12 cells. In virtually every case, the data 
define each measured constant to better than 
20%, giving high confidence in the measured 
values. The background colors in the table 
indicate which values differ by more than 30% 
(pale blue or red) or more than 2-fold (dark 
colors) from the previously published WT 
values (14). In all cases, these values are 
statistically different from the WT values 
(mostly at p<0.01; see Table 1) 
 
Implications of the data  
     These comprehensive data should be able 
to reveal any common patterns in the effects of 
these DCM mutations on the properties of the 
motor domain. However, the mutations are 
situated throughout the motor domain and 
there may also be local effects of the mutation 
specific to the site of each mutation. In looking 




for such patterns, the expectation is that such 
similarities should be distinct from those of the 
previously described HCM mutations (14, 15). 
The data, as displayed in Table 1, do not make 
any such pattern easy to establish. We have 
therefore redisplayed the data in a series of 
histograms (Fig. 4).   
      Fig. 4A presents the data for the affinities 
of actin for the motor domain in the rigor 
complex (KA), in the presence of ADP (KDA) 
and the apparent affinity of actin for myosin 
during the steady-state ATPase (Km). Note the 
salt concentrations used were lower in the 
ATPase assay (5 mM KCl) than in the KA and 
KDA measurements (25 mM KCl) and the 
temperature at 23 °C was 3 °C higher for the 
ATPase measurements than for the other 
kinetic assays.  
     7KHDIILQLW\RI:7ȕ±S1 for actin (KA) was 
10 ± 1.8 nM. In most cases, the affinity was 
weakened significantly by 25 ± 125%, the 
exceptions being I201T where it was similar to 
WT and S532P where it was apparently 
tighter, but such affinities (<10 nM) are 
difficult to measure with precision using our 
methods. In contrast, the DIILQLW\ RI ȕ-S1 for 
actin in the presence of saturating ADP (WT = 
109 nM) was in four mutants significantly 
tighter (50-80%) but weaker for the A223T 
mutant (250%). The two HCM constructs were 
also weaker (25% for R403Q and 100% for 
R453C). Thus, no simple pattern emerged 
from these affinities which defined the DCM 
phenotype as distinct from the two HCM 
mutants. 
      Fig 4A also includes the apparent affinities 
of ATP and ADP for sS1 (1/K1, and K6K7 
defined in Fig. 3).  All DCM mutations 
showed a major weakening of the affinity of 
ATP for sS1, while the two HCM mutations 
showed only small changes which may not be 
significant. In contrast, the ADP affinity for 
sS1 was generally tighter, but by a relatively 
small degree compared to the changes in ATP 
affinity. R237W is the exception which 
showed a 50% weaker ADP affinity. Since 
ATP and ADP do not bind to sS1 in the 
normal cross bridge cycle these events have 
little direct relevance to the DCM phenotypes, 
but no pattern emerges for the DCM vs HCM 
mutations.  
      In the case of ATP and ADP binding to 
actin.sS1 (1/K1¶ DQG .¶6K¶7 respectively), the 
ATP affinities had a modest tighter affinity 
(25-50%) except in the case of R237W (2-fold 
weaker). ADP affinities were weaker by 20-
30% except in the case of R237W (4-fold 
weaker), and the HCM mutation R453C 
(almost 2-fold weaker). Again there was no 
obvious pattern of behavior for the DCM vs 
HCM mutations. 
      Fig. 4B illustrates the changes in the 
measured individual rate constants for the 
ATPase cycle. Here the changes were 
generally smaller than for the equilibrium 
constant with no change compared to the WT 
values of more than 80% and mostly 
decreases. Overall, a pattern did not emerge of 
a common behavior of the DCM mutations. 
 The ATPase cycle 
    Values of the kcat & Km of the ATPase cycle 
for R403Q, R453C (HCM), and S532P (DCM) 
have been published (13, 14, 30) , while those 
for I201T, A223T, R237W, and F764L are 
presented in Table 1 and Fig S7. All kcat values 
for the DCM constructs were lower than WT 
(between 30% and 70%). By comparison with 
HCM mutations, one HCM mutation increased 
the kcat (R453C) by ~30%, and the other 
(R403Q) decreased by 17% (see Table 1 & 
Fig. 7). We modelled the complete cycle using 
all of our kinetic data and the ATPase values 
following the procedure we outlined in a 
recent paper comparing different myosin 
isoforms (16). Here, we modelled the ATPase 
cycle to provide estimates of the two missing 
parameters: the affinity of actin for the 
M.ADP.Pi complex 1/(K5) and the rate of Pi 
release from A-MADP.Pi (k+6). This allowed 
us to predict the occupancy of each myosin 
and actin.myosin states in the cycle as shown 
in Fig. 5. It is not clear what the effective actin 
concentration is in the rapidly shortening 
muscle (the nearest equivalent to the zero load 
conditions of the solution ATPase). In a 
rapidly shortening muscle, all active myosin 
heads have ready access to the actin as it 
moves past. Under isometric conditions, 
because of the mismatch of the thick and thin 
filament helicity, some myosin heads may 
have ready access to an actin site while 
another cannot attach to actin at all. We 
therefore modelled a range of actin 




concentrations ([A] = Km, 3 Km, and 20 Km; 
where the ATPase rate is 50%, 87% and 98% 
of kcat values, respectively) to facilitate 
comparison between the different mutant 
constructs under conditions that may match 
those of a contracting sarcomere. In addition, 
we attempted to model the situation when the 
muscle fibre is contracting under load. Here 
we used the estimate for the inhibition of the 
ADP release rate constant under 5 pN of load 
as defined from loaded single molecule assays: 
3-fold inhibition (31, 32). We included a 3-
fold reduction in both the ADP and Pi release 
rate constant to reproduce the expected ~3-fold 
reduction in ATPase cycling rate, which is not 
generated by a reduction in the ADP release 
rate constant alone.  
     The predicted occupancies are shown in 
Fig. 6. Note the color schemes are the same in 
both Fig. 5 and Fig. 6: red shades indicate 
detached cross bridges, yellow shades are 
weakly attached pre-force holding cross 
bridges and blue shades represent strongly 
attached force-holding bridges. The number by 
each pie chart represents the percentage of the 
pale blue, force-holding AÂMÂD state. The 
previously published WT data predict at low 
actin concentration ([A] = Km), almost 75% of 
cross bridges are detached with just 6.8% in 
the force holding blue states; dominated by the 
AÂMÂD state.  As actin concentration is 
increased, the detached states (red) decrease, 
the weakly attached states (yellow) increase, 
and the strongly attached AÂMÂD state doubles 
to 13%. The application of a 5 pN load at [A] 
= 3 Km increased the AÂMÂD state from 10.2% 
to 13.6% and increased the weakly attached 
states (mainly A-MÂT) at the expense of the 
detached MÂT state. A similar pattern was 
observed for all mutants studied. However, it 
is clear from an inspection of the images in 
Fig. 6 that all DCM constructs have a reduced 
occupancy of the force-holding, blue-shaded 
states and increases in the yellow, weakly-
attached bridges. The % of bridges in the 
force-holding AÂMÂD state is reduced in all 
cases, sometime quite dramatically from 10.2 
% at [A] = 3 Km for WT to < 3 % for S532P 
and R237W.   In contrast both HCM mutations 
have an increased occupancy of the AÂMÂD 
state (from 10.2 to 12.3 or 17.0% for R403Q 
and R453C respectively at [A] = 3Km). When 
bearing a load, all constructs increase the 
occupancy of the force-holding states (which 
is expected since load is modelled as a 
reduction of the rate at which ADP is released 
from AÂMÂD), but the extent of the increase is 
very variable. For WT, a 5 pN load increases 
the AÂMÂD state from 10.8% to 13.6% (an 
approximately ~1/3rd increase). In contrast, the 
increases are predicted to be much smaller for 
the DCM mutations; 0.2 % (<1/10th increase) 
for S532P & R237W and 0.8 ± 1.5 % for the 
other DCM mutations while the R453C HCM 
mutant has a larger 5.5% (1/3rd) increase in the 
AÂMÂD state. The second HCM mutation, 
R403Q, has more AÂMÂD than WT with no 
load (12.3%), but increases by only a moderate 
1.2% at 5 pN load which is an increase of 
1/10th (1.2%/12.3%).  
     These predictions for the lower occupancy 
of the AÂMÂD state during the ATPase cycle 
have the implication that in the steady-state, 
the DCM constructs will bear less load, hence 
need to activate more cross bridges to hold the 
same force as the WT. This is seen from the 
modelling under load when a 5 pN load is 
applied to a single motor. In contrast, the 
HCM mutation can bear a larger load as there 
will be more of the AÂMÂD in the steady state. 
      The effects on the key properties of the 
cross bridge cycle are summarized in Fig. 7 
where the measured kcat values for the WT and 
each mutant are shown alongside the duty 
ratio, predicted maximum velocity, the 
fractional occupancy of the AÂMÂD state and 
how load is predicted to influence these 
parameters. 
      A clear pattern from these data is that the 
predicted duty ratios (dominated by the AÂMÂD 
state) are lower for 4 out of 5 DCM mutants 
compared to WT, while for the HCM mutants, 
the either no change or an increase is seen. 
This behavior is also seen under load and 
although the duty ratio increases under load, 
the duty ratio remains lower than WT for the 
DCM constructs.  
   A recent study has completed a single 
molecule laser trap study of three of the DCM 
mutations used here (33). This work estimated 
the duty ratio and the load dependence of the 
ADP release rate constant for each mutant.  A 
maximum 10% change in the load dependence 
of ADP step compared to WT was reported, 
and this was not statistically significant. At the 




same changes in duty ratio were similar to 
those estimated here. 
      The predicted velocity of shortening was 
estimated from Vo = d.ATPase/DR in each 
case where d is the step size (assumed to be 
invariant) and the measured ATPase and the 
predicted duty ratio (DR) values. Note, as the 
ATPase and duty ratio have a similar strong 
dependence on actin concentration, the 
velocity is independent of actin concentration. 
As shown in Fig. 7 for kcat of the ATPase and 
the predicted maximum velocity of shortening, 
there is no common pattern for DCM and 
HCM constructs.  
Discussion 
      Overall our data show only one difference 
which is common to four of the five DCM 
mutations, a reduced duty ratio (compared to 
WT) due to a lower occupancy of the force-
holding AÂMÂD state and this position is even 
clearer once the myosin cross-bridge is 
exposed to a 5 pN load. All other parameters 
assessed vary between the different mutations 
and so reflect local influences of the mutation. 
The net result in each case is reduced force-
holding capacity in the steady-state. 
      What of the prediction that DCM & HCM 
mutations would be expected to show distinct 
behaviors?  We have included our previously 
published kinetic data for two HCM 
mutations, R453C and R403Q, in Fig 4 (grey 
bars). These again indicate no common pattern 
for the two HCM mutation nor a clear 
difference between the HCM and DCM data. 
The kcat data for the ATPases are listed (see 
Table 1 & Fig. 7) and while one HCM 
mutation increased the kcat by ~30% (R453C) 
and the other (R403Q) decreased by 17%. 
Note that all DCM mutations have a lower kcat 
than the HCM mutations. The modelling of the 
ATPase cycle for R453C was included in our 
2017 publication (16), and here similar 
analysis is reported for the R403Q mutation. 
The data are all included in Fig. 6-8 for 
comparison to the DCM data. Strikingly, Fig. 
6 shows that in contrast to the DCM 
mutations, both HCM mutations have a higher 
duty ratio and an increase occupancy of the 
AÂMÂD state (from 10.2 to 12.3 or 17.0% for 
R403Q and R453C respectively at [A] = 3Km). 
While the R453C HCM mutant has a larger 
5.5% (1/3rd) increase in the AÂMÂD state. The 
second HCM mutation, R403Q, has more 
AÂMÂD than WT with no load (12.3%), but 
increases by only a modest 1.2% at 5 pN load. 
The modeling thus predicts that DCM 
mutation all predict a lower force-holding 
capacity in the steady-state while HCM 
mutations will have a higher force-holding 
capacity.  
How do the Mutations Cause DCM? 
       This remains a difficult to answer 
question. The often repeated argument that 
HCM is a hyper- contractile phenotype while 
DCM is hypo-contractile derives from clinical 
echocardiographic data as well as contractility 
of some mouse models (34). The data have 
sometimes been used to predict hypo- and 
hyper-activity of individual myosin mutations, 
but this will depend upon which parameter is 
measured and in what isoform of myosin and 
what species. As shown in Fig. 7, a mutant 
myosin can be hypoactive in the kcat of the 
ATPase activity and either hypoactive 
(A223T) or hyperactive (R237W) for velocity 
of shortening.   The R453C HCM mutation has 
an increased duty ratio (better at holding force) 
yet lower velocity of shortening. Each 
parameter needs to be considered in terms of 
how it contributes to the overall performance. 
In addition, the data presented here are those 
expected for actin.myosin at full activation. 
The cardiac sarcomere is rarely fully activated, 
so how these results would be interpreted at 
submaximal activation also needs to be 
considered. 
Activation & relaxation of contraction 
      Calcium regulation of the thin filament is 
perturbed by DCM or HCM mutations in the 
regulatory proteins, troponin & tropomyosin 
and can result in loss or gain in calcium 
sensitivity (a decrease or increase in the 
calcium concentration required to half activate 
contraction). For many mutations in thin 
filament proteins, a gain of calcium sensitivity 
is associated with HCM (35). The link 
between calcium sensitivity and DCM is not 
so clear cut; some in vitro work suggests a loss 
RIVHQVLWLYLW\ WRȕ-adrenergic stimulation (36±
39). Calcium sensitivity is also a function of 
the myosin ATPase cycle, as strongly bound 
cross bridges can help activate the thin 




filament (40, 41). Thus, myosin mutations 
which increase the occupancy of the strongly 
bound states (and increase duty ratio) such as 
the two HCM mutations used are expected to 
increase calcium sensitivity and vice versa for 
the DCM mutation which decrease the duty 
ratio). This operates in the same way that 
reduction in ATP concentration or elevated 
ADP concentrations increase the duty ratio by 
slowing the detachment of rigor bridges 
reducing calcium sensitivity.   
        The importance of activation of 
contraction via the thick filament has recently 
been highlighted (42, 43). Trivedi et al 
highlighted potential of mutations in the 
myosin motor domain, myosin LC, S2 and 
MyBP-C to alter the balance between relaxed 
and active states of the thick filament by 
altering the interaction between the myosin 
motors and the relaxed thick filament (42). 
The authors argue that this may be a common 
mechanism by which a large class of HCM 
mutations can produce hypercontractility ± 
that is by increasing the number of myosin 
motors available for contraction. Many of the 
DCM residues studied here are buried and so 
are unlikely to affect motor domain-thick 
filament interaction directly. However, the 
other route by which myosin mutations can 
alter thick filament regulation is by altering the 
occupancy of the detached M.ADP.Pi state. 
This state (post recovery-stroke, with switches 
1 & 2 closed) is a prerequisite to form the 
stable so-called J-motif or interacting heads 
which form in the relaxed thick filament (44±
46).  Under relaxed conditions the proportion 
of M.D.Pi is controlled by the equilibrium 
constant K3 (Fig. 3). Any change here induced 
by a mutation could alter the balance between 
relaxed and active cross bridges in the thick 
filament. During contraction, the proportion of 
myosin as M.ATP will be influenced by the 
equilibrium constant K3, if the hydrolysis step 
can be treated as a rapid equilibrium step (k+3 
+  k
-3 >>  kcat), or by the value of k+3 +  k-3 if k+3 
+  k
-3 is of the same order as  kcat. 
Energy balance  
      One suggestion for the causes of HCM and 
DCM phenotypes is that mutations induce a 
change in the energy balance of the 
cardiomyocytes by altering the efficiency with 
which the energy of ATP is utilized. This can 
be appreciated by estimating the energetic cost 
of force generation and movement. Here the 
kcat of the ATPase when generating 5 pN of 
force from Fig. 7 divided by 5 gives an 
energetic cost/pN force. This is shown in Fig. 
8A and estimates that individual WT ȕ-cardiac 
myosin motors (or carrying either HCM 
mutation) use between 0.35 and 0.45 ATP sec-
1
 per pN load, while myosin carrying any of 
the DCM mutations use 0.1 - 0.25 ATP sec-1 
for the same pN load.   
      In contrast, the energy used during 
unloaded shortening is given by kcat x DR/d. 
That is DR (the fraction of the ATPase cycle 
when movement is generated which estimates 
the minimum number of myosins needed for 
smooth movement) divided by the step size d 
gives the ATP used per sec for each nm of 
travel. As shown in Fig. 8B, this also suggests 
a distinction between HCM and DCM 
mutations. WT myosin used 0.16 ATP/sec/nm 
of movement at maximum velocity under zero 
load while the two HCM constructs predict a 
higher ATP usage, 0.214 and 0.247 
ATP/sec/nm. In contrast, each DCM mutation 
is predicted to use much less ATP, the 
velocities are slower (Fig. 5), but the ATP 
usage is also lower at between 0.014 to 0.106 
ATP/sec/nm (10 - 66% of WT values). 
    The estimates suggest that the DCM 
mutations generate less force and contract 
more slowly than WT myosin. The constructs 
also use ATP more economically at both high 
force and during high velocity contractions. 
The two HCM mutations are more similar to 
WT in terms of the economy of force 
generation, while they are significantly less so 
for low load velocity. 
     An important caveat to the calculations 
presented here is that these are based on 
transient and steady-state biochemical kinetic 
assays. They assume that the step size d and 
the myosin stiffness remain unchanged by 
each of the mutations. A change in step size d 
will alter the distance moved in each ATPase 
cycle and will therefore alter the velocity of 
movement. A change in the step size or the 
stiffness of the motor domain will alter the 
force generated/held by each cross bridge. A 
recent study by (33) has shown that the load 
dependence of the ADP release step does not 
change significantly compared to wild type for 




3 of the DCM mutations studies here. Few 
VWXGLHV RI WKH VWHS VL]H IRU PXWDWLRQV LQ ȕ-
cardiac myosin have been made but estimates 
of the step size for S532P are not 
distinguishable from WT (JS & KR 
unpublished).  
Comparison of predicted and measured in 
vitro velocities 
      In vitro motility measurements have been 
published for both of the HCM and one of the 
DCM mutations used here (13, 14, 30). 
Unpublished data has been collected by Choe, 
Ruppel, and Spudich (personal 
communication) for the other DCM mutations 
with the exception of F764L. Each of these 
motility measurements used a construct with a 
C-terminal tag to allow specific attachment of 
the motor domain to the surface. Figure 9 
shows the mean velocity of the top 5% of 
smoothly moving filaments, normalized to the 
WT values, compared with our predictions 
(data in Figure 7 and Suppl. Table 5). A more 
complete analysis of the motility data is given 
in Suppl. Table S1. The normalization to the 
WT values allows comparison between the 
two data sets despite the different constructs 
and different experimental conditions used. 
Caution must be taken with such comparisons 
as a large number of measurements, each with 
its own error of the order of 20%, go into the 
calculation. When comparing experimental 
with predicted values, there is a correlation 
between the two values for 4 out of 6 of the 
mutations (2 DCM, 2 HCM) and the other 2 
DCM mutations (S532P & R237W) show a 
predicted change which were ~35% greater 
than measured. For these two mutations the 
calculation was affected by the very small 
estimates of the duty ratio, < 0.05 in each case. 
A small error on this estimate can therefore 
have a large effect on the estimated velocity. 
In conclusion where the estimate of the duty 
ratio is precise enough, there is a good 
correlation between the predicted and 
measured values, but the correlation breaks 
down when the duty ratio becomes too small 
to estimate with sufficient precision. 
     Testing our model predictions against 
experimental data will require more carefully 
matched experimental conditions and 
independent assessment of the steps size for 
the same constructs. Note, our velocity 
calculations assume a constant step size for all 
of the mutations used here, which to date have 
not been measured. 
Conclusions 
     The results presented here establish that the 
mutations alter individual steps in the ATPase 
cycle based on their specific location in the 
motor domain, but no common pattern has 
emerged for effects on specific steps 
associated with either HCM or DCM 
mutations. However, when the cycle as a 
whole is considered, DCM and HCM 
mutations appear to alter the overall balance in 
the cycle in distinct ways. DCM mutations 
result in lower kcat for the ATPase, a lower 
occupancy of the force-holding AÂMÂD state 
and hence, a lower duty ratio. The occupancy 
of the AÂMÂD state and the duty ratio is 
increased by a 5 pN load, but less than for the 
WT. Using these values to estimate the 
efficiency of ATP usage predicts that all DCM 
mutations here use less ATP to hold a 5 pN 
load than WT, while most also use less ATP to 
move 1 nm at maximum velocity. Collectively, 
this study suggests that there is an overall loss-
of-function concerning steady-state and 
motility parameters, leading to a deficit in 
force generation due to the reduced occupancy 
of the force-holding AÂMÂD state. 
    The same type of analysis of the two HCM 
mutations indicates a distinct behavior in 
several respects. The AÂMÂD state has higher 
occupancy than WT, and hence a higher duty 
ratio. A 5 pN load for the R453C mutation 
increases the AÂMÂD state occupancy by 1/3rd,
 
much less for the R403Q mutation. The kcat for 
the ATPase and the predicted velocity of 
shortening for the two HCM mutations, 
change in opposite directions. In terms of ATP 
usage, the two HCM mutations both show a 
significant increase in the ATP used at high 
velocities than WT (the opposite of the DCM 
mutations), but a similar amount of ATP 
needed per pN force to that of WT and more 
than the DCM mutations.  
    Thus, we have identified distinct differences 
between the HCM & DCM mutations in how 
they alter the mechanochemical cycle. DCM 
mutation show loss of contractile function 
across a range of properties while HCM 
mutations have increased force generating 




capacity, but require greater ATP usage at high 
velocity compared to WT. How such changes 
result over a long period in the HCM or DCM 
phenotype, remains to be explored. 
   The results presented here are for the 
behavior of a fully activated cross bridge, yet 
cardiac sarcomeres are rarely fully activated. 
Additional factors will come into play at 
submaximal activation where the altered 
behaviour of the myosin heads will have 
secondary allosteric cooperative effects on 
both thick and thin filament activation. 
Importantly, the exact balance of properties of 
a specific mutation on contraction is likely to 
depend on the degree of penetrance in 
individual patients. This is an important 
consideration when extrapolating from studies 
with pure mutant proteins to the highly 
cooperative thick and thin filaments of the 
sarcomere. 
     Recently, there has been a resurgence of 
interest in the role of myosin thick filament 
regulation in defining the cooperativity of 
contractile activation and relaxation. For a 
review see (42, 43).  The role of DCM and 
HCM mutations in such processes is only just 
beginning to be considered.   Spudich (2015) 
noted that many HCM mutations appear on a 
surface of the motor domain which was termed 
the myosin mesa. The role of this myosin 
surface and its HCM mutations in the 
regulation of myosin activity via head-head 
interactions, in parking the heads onto the 
thick filament and interactions with MyBP-C 
have been explored by (42, 47). Trivedi et al 
point out that such a mechanism can explain 
the hyper contractility phenotype of HCM by 
increasing the availability of myosin heads to 
contribute to contraction (42). In the final 
analysis, the effects of mutations on both the 
crossbridge cycle and on the 
activation/relaxation processes will need to be 
considered. 
Experimental Procedures 
Protein Expression & purification 
     The production of adenovirus carrying the 
MYH7 motor domain and mutations therein as 
well as the infection and culturing of C2C12 
cells were performed as described in (48). 
Recombinant human short sub-fragment 1 
ZLWKDVLQJOH,4GRPDLQȕ-sS1) for both WT 
and DCM-causing mutations were co-
expressed in C2C12 cells with a His-tagged or a 
FLAG-tagged human ventricular essential 
light chain (ELC). For steady-state ATPase 
studies, the sS1 construct included a C-
terminal eGFP moiety (13), and the sS1 used 
for in vitro motility studies included a C-
terminal 8 amino acid affinity clamp tag (30). 
The adenoviral particles were amplified using 
HEK293 cells; the viruses were purified using 
CsCl gradients, and the concentrated virus was 
stored in a glycerol buffer at -20 °C as 
previously described (27). 
     ȕ-sS1 with a single ELC were purified by 
infecting C2C12 cells for 4-5 days and frozen 
into cell pellets. Pellets were then 
homogenized in a low salt buffer and 
centrifuged, and the supernatants were purified 
by affinity chromatography using either a 
HisTrap HP 1-ml column (His-ELC) or anti-
FLAG resin (FLAG-ELC). In the case of His-
tagged ELC based purification, the sS1 was 
dialyzed into the low salt stopped-flow buffer 
(25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 
1mM DTT, pH 7.0).   
   The sS1 elutes with a single light chain and 
what is assumed to be a small amount full-
length endogenous myosin which presumably 
binds the tagged light chain (Fig 2). Dialysis in 
low ionic strength stopped-flow buffer reduces 
the endogenous myosin to between 0.0 and 
2.85 % by molar ratio of motor domains. This 
is too low to have a significant effect on the 
transient measurements reported here. For 
FLAG-ELC based purification, the sS1 was 
eluted from the anti-FLAG resin with excess 
FLAG peptide, and the eluate was run over an 
anion exchange column (HiTrap Q 1-mL 
column) as described in (13). 
   Actin was prepared from rabbit muscle as 
described by (49). The actin was labelled with 
pyrene at Cys-374 as described by (50). For 
use at concentrations below 1 µM the actin 
was stabilized by incubation with phalloidin in 
a 1:1 mixture at 10 µM for several hours 
before use. 
ATPase 
    Steady-state actin-activated ATPase 
DFWLYLWLHVIRUȕ-WT sS1 and the human cardiac 
mutant myosins were determined at 23°C 
using a colorimetric assay to measure 




inorganic phosphate production at various time 
points from a solution containing sS1, ATP, 
and increasing amounts of actin filaments (51). 
Assay buffer conditions were 10 mM 
imidazole, 5 mM KCl, 4 mM MgCl2 and 1 
mM DTT. Kinetic parameters (i.e., kcat) were 
extracted from the data by fitting to the 
Michaelis-Menten equation using the curve 
fitting toolbox in MATLAB (52) . 
Transient Kinetics 
     All kinetic experiments were conducted in 
20 mM MOPS buffer with 25 mM KCl, 5 mM 
MgCl2, and 1 mM DTT, pH 7, at 20 °C, unless 
otherwise indicated. Measurements were 
performed with a High-Tech Scientific SF-61 
DX2 stopped-flow system. The concentrations 
stated are those after mixing in the stopped-
flow observation cell unless otherwise stated. 
All stopped-flow traces were analyzed in 
either software provided by TgK Scientific 
(Kinetic Studios) or Origin (Microcal). 
Intrinsic tryptophan fluorescence was 
measured by excitation at 295 nm and 
observed through a WG320 filter. In the 
absence of actin, the kinetics of S1 and ATP or 
ADP were interpreted using the seven-step 
model (53) (see Fig. 3), where the forward rate 
constants, in the counter-clockwise direction 
are k+i and the reverse rate constants are 
denoted k
-i and equilibrium constant  Ki = k+i/k-
i. In the presence of actin, the data were 
interpreted in the equivalent scheme also 
shown in Fig. 3 (running clockwise) where the 
numbering of the reaction steps carry a prime 
e.g. k,¶, k-,¶, KL¶. The exception is the 
hydrolysis step (step 3) which is common to 
both cycles and is given as step 3 (no prime). 
The full details of each experimental 





   With the set of rate and equilibrium 
constants measured here and estimates of the 
kcat and Km values it is possible to model the 
cycle in the steady-state of ATP hydrolysis. 
Using the 8-state model of the actin.myosin 
ATPase cycle (shown in Figure 5) and our 
measured constants we were able to fit the 
model to the kcat and Km values to provide 
estimates for the actin affinity for M.D.P  (KA) 
and the rate constant for Pi release  (k+Pi). Note 
briefly, under standard steady state condition 
the Pi and ADP concentrations are assumed to 
be ~0. Thus there is no rebinding of the 
products, Pi and ADP. This cycle can be 
modelled using any proprietary kinetic 
modelling program. We used the in-house 
MUSICO software as presented in (16) 
(available at 
www.mijailovichlab.org/download)  as this 
allows fitting of the data to the steady-state 
parameters and provides error estimates of the 
fits, including the resolution matrix, which 
provided an estimate of the co-dependence of 
fitted parameters. As in our earlier modelling 
ZRUN RQ WKH ZLOG W\SH :7 ȕ-cardiac and 
other myosin isoforms, all fitted parameters 
are well defined to a precision of ~ 20%.  The 
resolution matrix values are consistent with 
parameters having low co-dependence 
(diagonal values close to 1). The exception 
being k
-T which cannot be resolved from our 
current data. The fitted values of all constants 
and the resolution matrices are listed in the 
Supplementary material (Tables 1 & 2). 
We modelled the effect of load on the cycle as 
set out in our 2017 paper (16). An estimate of 
the load dependence of ADP release comes 
from direct measurements of the effect of load 
on the lifetime of the AMD state (refs 31, 32).  
We used 5 pN load as an arbitrary value close 
to that thought to be likely for a muscle fibre 
under isometric tension and the calculation 
suggests a 3-fold reduction in ADP release rate 
constant.  Such a reduction in ADP release rate 
constant has little effect on the cycling rate of 
the system (ATPase). This is because the ADP 
release is 5-10 fold faster than kcat and the 
reduction in the ADP rate constant is partially 
compensated by an increase in the occupancy 
of the AMD state. The combination of effects 
leaves the flux through the cycle little effected.  
Yet there is a well know inhibition of ATP 
turnover for a muscle fibre contracting against 
a load.  For an isometric fibre the ATPase has 
been estimated to be ~1/3rd of the ATPase for a 
rapidly shortening muscle a manifestation of 
the Fenn effect (54).  The rate of entry into the 
force holding or force generating state is 




expected to be inhibited by load on 
thermodynamic arguments and is built into 
most models of the mechanical cross bridge 
cycle (55, 56).  We therefore applied a 3-fold 
inhibition of the ATPase cycling rate by 
reducing the entry in to the force holding state, 
kPi in our model.  This assumes that the effect 
of load is similar on both Pi and ADP release 
steps. Such a model is not meant to be 
definitive but to illustrate the order of effect 
expected on the cycle. 
Error analysis 
In our previous paper (16), where we 
established this modelling approach, we 
demonstrated that varying any one of the fitted 
parameters (kH, , k-D, KD*, k-D*, k-T*, KT*) by plus 
or minus 20%  has minimal effect on the best 
fit values of the remaining parameters I.e. the 
values varied by much less than 20%.   This 
confirmed the results of the sensitivity matrix 
that apart from k
-T the parameters are well 
defined by the fitting procedure.  This 
observation remains true for the data presented 
here (see, resolution matrices, Table S3).  Here 
we additionally examined the influence of a 
change of 20% in the values of kcat & Km, used 
to define the fitted parameters.  
Km is largely controlled by the value of KA.  If 
Km is altered by ±20% then the value of 1/Ka 
(1/Ka is used to have both in units of µM) 
changes by 20%.  All other fitted parameters 
change by less than 5 %. This is illustrated for 
the WT type data in Table S7.   
A 20% change in kcat changes the flux through 
the system.  For species like AMD the rate 
FRQVWDQW N¶+6 is fixed at the measured value.  
To change the flux through this step requires a 
20% change in the concentration of AMD.  
Thus AMD changes in line with the change in 
kcat. 
The effect of a change in kcat on the fitted rate 
& equilibrium constants is variable dependent 
upon how each rate constant contributes to the 
kcat value and this differs for each mutation.  
Since for most mutants A-MDPi is the pre 
dominate species in the steady-state at high 
actin concentration, kPi will change to a similar 
extent as the change in kcat. That is the flux 
though Pi release step (essentially irreversible 
because [Pi] = 0) is equal to the ATPase rate 
thus kcat = kPi x [A-MDPi]/[M]total and when 
actin is close saturation more than 60% of the 
myosin is in the A-MDPi state (see Fig 6 and 
Table S4) resulting in  kPi = 1.2 ± 1.5 x kcat .   
Thus varying kcat by plus or minus 20% and 
refitting the data to generate new best fit 
parameters has a significant effect on kPi 
(changes by ~20%) but little effect on any 
other value.  This is illustrated most clearly by 
the + 20% data sets for S532P (no other fitted 
value changes by >3.2%) and F764L (no value 
changes by >8.3%; see data in Table S6) and a 
similar result is seen for A223T, R237W and 
R403Q.  A decrease in kcat of 20% can be more 
significant depending on the relationship to 
other steps in the cycle, namely kH (see 
discussion below) 
At the other end of the scale are wild type and 
R453C where kPi only partially limits the 
cycle.  In the case of wild type A-MDPi is ~ 
35% of the total myosin at saturating actin and 
the hydrolysis step is a significant contributor 
to the overall kcat, i.e.  kH   is similar to kpi.   
Changes of +20% in kcat result in 30% change 
in kPi and 20% change in kH. For R453C   27% 
of the total myosin is as A-MDPi and 29% as 
MT thus there is a significant shift towards the 
hydrolysis rate becoming limiting on the cycle 
as reported in (15).  A change in kcat now has a 
larger effect on both kPi (up to 50%) and kH 
(16%) and this also results in a change in KA. 
 
Unloaded in vitro motility 
    Motility measurements were carried out as 
described in (30, 57). Coverslips were coated 
with nitrocellulose and mounted on glass 
slides with double-sided tape for sample 
separation. sS1 with a C-terminal 8 amino acid 




affinity clamp was attached to the coverslip 
via PDZ-18 anchor (30, 58). Actin filaments 
were monitored using a 1003 objective on a 
Nikon TiE microscope with at least four 30-s 
movies recorded for each condition. The mean 
velocity (MVEL) was calculated using the 
FAST software (30). We only report here the 
MVEL for the top 5% of fastest filaments and 
then normalized those values to WT. All 
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Parameter WT I201T A223T R237W S532P F764L 
N=3 N=3 N=3 N=3 N=3 N=3 
ATP-binding to S1       
K1k+2 (µM-1 s-1) 5.8 ± 0.2 2.9 ± 0.5** 1.3 ± 0.07***   0.7 ± 0.06*** 2.7 ± 0.2*** 3.3 ± 0.3**   
k+3 + k-3 (s-1) 91.2 ± 10.6 72.2 ± 4.4 73.6 ± 8.1 79.7 ± 4.0 137.3 ± 6.0* 166.8 ± 5.6**   
1/K1 (µM) 15.9 ± 2.2 26.4 ± 5.9 56.8 ± 6.5** 117.8 ± 7.0*** 50.6 ± 1.1*** 52.8 ± 5.0**    
       
ADP-binding to S1       
K6K7 (µM) 0.53 ± 0.06 0.21 ± 0.03** 0.25± 0.01***    0.790 ± 0.124* 0.171 ± 0.01** 0.27 ± 0.04**   
k+6 (s-1) 0.63 ± 0.03 0.31 ± 0.01*** 0.1 ± 0.00 ***   Not measurable 0.4 ± 0.0** 0.34 ± 0.02***   
       
ATP-binding to actin·S1       
K͛1k͛+2 (µM-1 s-1) 4.4 ± 0.3 2.8 ± 0.07* 5.0 ± 0.3 0.65 ± 0.07*** 2.8 ± 0.03* 3.9 ± 0.4 
K͛1k͛+2 (µM-1 s-1) at 10 °C 2.7 ± 0.09 2.0 ± 0.2* 3.1 ± 0.1 0.39 ± 0.02*** 2.0 ± 0.03** 2.5 ± 1 
1/K͛1 (µM) at 10 °C 365.7 ± 17.7 230.7 ± 29.0* 161.3 ± 14.9***    1061.3 ± 67.1*** 197.2 ± 3.0*** 269.5 ± 30.3 
k͛+2 (s-1) at 10 °C 991 ± 18.2 455.4 ± 22.0*** 497.3 ± 27.8***    407.8 ± 14.0*** 405.3 ± 4.2*** 601.2 ± 23.8***   
Kɲϭ at 10 °C 3.6 ± 0.3 2.6 ± 0.2 2.1 ± 0.03** 3.5 ± 0.4 2.2 ± 0.2* 3.5 ± 0.1 
kнɲϭ (s-1) at 10 °C 78.9 ± 0.7 52.7 ± 5.5** 34.0 ± 0.5***   45.5 ± 3.4*** 53.5 ± 2.6*** 40 ± 2.7**   
       
ADP-affinity for actin·S1       
K͛6K͛7 (µM) 6.1 ± 0.7 7.4 ± 0.6 8.3 ± 0.4 29.4 ± 2.6*** 7.9 ± 0.3 8.5 ± 0.7 
k͛+6 (s-1) 58.7 ± 3.3 51.6 ± 2.3 42.3 ± 1.7*  101.6 ± 2.8*** 62.0 ± 3.0 51.8 ± 2.8 
K͛7k͛-6 (µM-1 s-1) 9.6 7.0 5.1 3.5 7.8 6.1 
Kɲ No second phase 11.5 ± 3.2 No second phase No second phase 7.1 ± 1.5 6.2 ± 1.8 
kнɲ (s-1) No second phase 8.9 ± 1.7 No second phase No second phase 8.4 ± 0.7 12.1 ± 3.6 
K͛6K͛7 / K6K7 11.5 35.2 33.2 37.2 46.2 31.5 
       
S1-affinity for actin       
KA eq. (nM) 10 ± 1.8 10.5 ± 2.5 32.9 ± 3.0**    13.6 ± 0.8 5.3 ± 1.4 12.5 ± 0.9 
KDA (nM) 109.3 ± 13.8 28.3 ± 1.6** 382.9 ± 59.9 *   12.8 ± 0.9** 41.0 ± 6.8** 45.3 ± 2.2** 
KDA / KA 10.9 2.7 11.6 0.94 7.7 3.6 
Km (ʅM)ΐ 53.0 ± 5 (19) 46.33 ± 8 (6) 32.6 ± 6 (6) 105.5 ± 30 (4)* 74.9 ±  31 ± 10 
kcat (s-1) ΐ  5.5 ± 0.2 (19) 3.63 ± 0.3 (6)*** 4.09 ± 0.3 (6)** 2.86 ± 0.5 (6)*** 1.81 ± 0.1 (6)*** 4.01 ±  




Table 1. Measured parameters for the WT and 5 DCM linked mutations  
9DOXHVIRUȕZLOGW\SHP\RVLQIURPNag et al. 2015 
Values differ significantly from wild type, * p < 0.05, ** p < 0.01, *** p < 0.001 
Color code indicated degree of difference to wild type.  Blue: slower rate constants or weaker equilibrium values, red: faster or stronger values.  Pale color 
>30% <2 fROGFKDQJHGDUNVKDGH-fold change compared to wild type.  
ÁFor the steady state measurements the data are the mean (± SEM) values from 4-6 independent measurements except the WT which was the average from 
19 samples.   
Experimental conditions:  buffer 25 mM KCl, 5 mM MgCl2 P00236S+Û&except the ATPase ΐ  data which used 10 mM imidazole, 5 mM 


















Figure 1. Structure & location of DCM mutations in the myosin motor domain. (A) Structural 
model of the motor domain of ȕ-cardiac myosin (based on PDB-4P7H). The main chain is shown as a 
ribbon diagram with the side chains of residues mutated in DCM patients and used in this study are 
shown in space filling form. Some key elements of the structure are highlighted in colour to help 
orientate the reader. (B)  Conservation of mutation sites in the myosin family. Example sequences are 
shown. The 5 residues are conserved for MYH7 in over 82 mammalian species (data not shown). 
Residues 237 and 764 are arginine and phenylalanine respectively across all myosins examined, 
emphasizing the functional importance of domains like the Switch-1 and the converter domain and 
their highly conserved nature. S532 is conserved in all mammalian myosin II and several other 
eukaryotes. A223 is conserved in cardiac and some skeletal isoforms in most mammals. I201 is 
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Figure 2. Image of a typical SDS-3$*( JHO RI WKH KXPDQ UHFRPELQDQW ȕ-sS1 during 
purification. After the molecular weight markers (Lane 1) the fractions from His trap column are 
shown (Lanes 2-6) followed by the pooled fractions, after dialysis, at two loading levels (Lanes 7 & 
8). The contaminant C2C12 full-length myosin is estimated as ~1% by weight or 0.5% by molar ratio 


















Figure 3. A minimal ATPase cycle for the myosin (7-step) actin.myosin (9-step) ATPase cycle. M 
is myosin, A is actin, T is ATP, D is ADP and P is inorganic phosphate. In a complex, dot means tight 
interaction between the components, e.g. A·M·D and hyphen indicates a relatively weak association, 
e.g. A·M-D. The rate constants for steps (i) that we experimentally determined are given as k+i in the 
forward (direction of ATP hydrolysis) and k
-i the reverse direction with Ki defined as k+i/ki. The 
background colors of the given states correspond to the intermediates in the cross bridge cycle in Fig 































































Figure 4.  Summary of all of the % change in each of the parameters measured in this study 
compared to wild type. (A) % change compared to WT for measured dissociation constant (KA, 
KDA), apparent Km or equilibrium constant for each of the steps as defined in Fig 3. (B) % change in 












Figure 5. Actin.myosin ATPase driven cross bridge cycle. The three black circles represent three 
actin monomers. The other symbol represents the myosin motor domain. The large ellipse represents 
the majority of the myosin motor domain with the actin binding site split by a cleft which is closed 
when tightly bound to actin. The smaller ellipse represents the converter domain and the rod the lever 
arm/light chain binding region. Strongly attached (to actin) force holding states of the myosin are 
shown in blue shades (progressively darker going towards the rigor-state. Weakly attached states 
(yellow shades) and detached states (red shades) are shown with the cleft open. Nucleotide and Pi 
binding and release steps are indicated in cerise and green lettering indicates the equilibrium constants 
for each step of the cycle defined in the clockwise (ATP hydrolysis) direction. The steps are labelled 
with equilibrium constant for each step in the forward direction as define by Mijailovich et al 2017. 












Figure 6. The occupancy of each of the intermediates in the ATPase cycle. Color coded to match 
those shown in Scheme 1. The occupancy is shown at three actin concentrations where [A] = Km, 3Km 
and 20Km. In addition, the result of what is predicted to happen to the state occupancies if the myosin 
bears a load of 5 pN at [A] = 3 Km.  







Figure 7. The calculated values for Duty ratio, maximum velocity, kcat for the ATPase cycle and 
occupancy of the force holding AÂMÂD state. For each of the constructs used, plus those of 
previously published HCM mutation (R403Q and R453C). The horizontal dotted line indicates the 
value for the WT protein. The vertical dash/dot line separates the HCM and DCM mutations. The left 
bar charts (red) are the values based on the measured rate and equilibrium constants. The right hand 
bar charts are the predicted results if the myosin carries a 5 pN load. 








Figure 8. Economy of force generation and velocity for the DCM & HCM constructs. (A) ATP 
used per sec per pN force while generating 5 pN force at [A] = 3Km. (B) ATP used per sec at 
maximum velocity of shortening.  i.e.  At kcat for the ATPase ([A] = 20 Km) and zero force (kcat for the 
ATPase x DR/ d). Since ATPase and DR have the same dependence on [A] this calculation is the 
same at all concentrations of actin above Km and only breaks down when the actin concentration 
becomes too low to maintain constant speed. 







Figure 9. Comparison of normalized in vitro motility values to the predicted velocity of 
shortening. The solid coloring depicts the top 5% mean velocity values measured experimentally 
through unloaded in vitro motility and analyzed by the filament tracking software described by 
(Aksel, 2015). The bars with hatched patterns are the values predicted from the kinetic analysis as 
described by (Mijailovich, 2017) and given in Fig 7 and Supplementary Table 5. Similar to the 
modeling analysis, we are comparing the DCM mutations to the HCM mutations. Note: no data has 
been collected for the F764L mutant. 
 
 
